Core Insights - Ailan Health Holdings, a leading Chinese nutritional supplement exporter, is reportedly seeking to sell its controlling stake, with a valuation potentially exceeding $1.5 billion (approximately 10.8 billion RMB) [2] - The company has engaged Goldman Sachs to connect with potential buyers, including strategic investors and private equity firms, with several institutions already entering preliminary due diligence [2] - The transaction may involve a combination of "old share transfer + capital increase," allowing buyers to acquire shares from the founder and some financial shareholders while injecting funds for capacity expansion and acquisitions in the U.S. and Europe [2] Company Background - Ailan's predecessor, Jiangsu Jingjiang Glucose Factory, was established in 1990 and evolved into a global leader in vitamin C raw materials, known as Jiangshan Pharmaceutical [3] - The company registered the "Ailan" trademark in 1997 and shifted its focus to nutritional supplement contract manufacturing under the leadership of Chairman Chang Liang in 2006 [3] - Ailan has grown to become one of the top three companies in the global nutritional product CDMO industry through a series of international acquisitions [3] Structural Considerations - Ailan operates as a typical "red-chip structure" enterprise, with its parent company registered in the Cayman Islands, which poses compliance challenges for an A-share listing [3] - The potential sale, if successful, could represent one of the largest mergers and acquisitions in China's health industry in recent years, potentially impacting the industry landscape significantly [3]